Year: 2024

Takeda_Logo

U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease

− ENTYVIO is Now Available in the U.S. in Both IV and Subcutaneous Administrations for Maintenance Treatment of Adults with...

logo-69

$65+ Billion Logistics Automation Markets – Global Forecast to 2031: Increasing Focus on Improving Last-mile Deliveries and Growing Use of AI in Supply Chain – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Logistics Automation Market by Offering (Hardware, Software, Services), Type (Inbound, Outbound), Automation Mode, Application (Inventory Management, Others), End...

Group-brand-mark_H-Type_rgb_full-color

ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections